Sentences with phrase «as breast cancer patients»

Not exact matches

The essay «God as Monica's Breast» is worth the price of the volume, and the «Consenting to Die» essay, which discusses suicide and death as something to do» rather than just wait for, breaks into a fictional discussion between a doctor and a cancer patient.

My own experience as a patient began in the spring of 1983 when, in a routine mammogram, breast cancer was found.

Breast milk is incredibly healthy, and is even being used as a treatment for some cancer patients.

Also, there is no reporting of medical errors in the U.S., so we really don't have the data to draw conclusions, but the Institute of Medicine in 2000 reported that «at least 44,000 and perhaps as many as 98,000 Americans die in hospitals each year as a result of medical errors,» meaning that «deaths due to preventable adverse events in hospitalized patients exceed the deaths attributable to motor vehicle accidents (43,458), breast cancer (42,297) or AIDS (16,516).»

Patients should be reassured that Tamoxifen remains very effective in reducing the overall risk of recurrences and deaths from breast cancer, as the authors state.

The findings, presented at the 2016 San Antonio Breast Cancer Symposium in a poster session by Cameron W. Swanick, M.D., should serve as an important discussion point between older patients and their physicians when making treatment decisions.

Most of the time, he said, Watson affirms that the decisions he had already come to were correct, such as one breast cancer patient who needed aggressive chemotherapy.

The study has been tested in metastatic patients with different primary tumours such as breast, colon and lung cancer.

Vitamin C has previously been shown to be effective as a non-toxic anti-cancer agent in studies by Nobel Prize winner Linus Pauling and was recently shown to reduce mortality by 25 % on breast cancer patients in Japan.

Some breast cancer treatment agents, such as anthracyclines, can result in abnormal heart rhythms that in some patients are benign but in others can lead to life - threatening heart rhythms.

According to Dr. Gass, «In an era where we see more early - staged breast cancer patients choosing mastectomy, no study has previously addressed breast specific sensuality, defined as the breast's role during intimacy.

Breast cancer patients who have radiotherapy targeted at the original tumour site experience fewer side effects five years after treatment than those who have whole breast radiotherapy, and their cancer is just as unlikely to return, according to trial results published in The LBreast cancer patients who have radiotherapy targeted at the original tumour site experience fewer side effects five years after treatment than those who have whole breast radiotherapy, and their cancer is just as unlikely to return, according to trial results published in The Lbreast radiotherapy, and their cancer is just as unlikely to return, according to trial results published in The Lancet.

Fior and colleagues plan to do that with a larger group of colorectal cancer patients and with patients who have other types of cancer, such as breast cancer.

Ziskin, a Hollywood film producer who died of metastatic breast cancer, was a co-founder of Stand Up To Cancer, an initiative founded in 2008 by nine women in the entertainment industry to accelerate groundbreaking research and bring new treatments to patients as quickly as poscancer, was a co-founder of Stand Up To Cancer, an initiative founded in 2008 by nine women in the entertainment industry to accelerate groundbreaking research and bring new treatments to patients as quickly as posCancer, an initiative founded in 2008 by nine women in the entertainment industry to accelerate groundbreaking research and bring new treatments to patients as quickly as possible.

These studies enrolled a total of 12,361 patients diagnosed with a variety of cancers, including lung, breast, skin, and prostate, as well as blood cancers such as leukemia, lymphoma, and myeloma.

«Our findings suggest that this new drug combination would also help patients with this type of aggressive breast cancer as well as other cancers, such as lung, prostate and ovarian cancers,» Dr. Rassool says.

Dr. Mehnert noted that it was surprising that patients with a more treatable cancer, such as breast cancer, experienced more distress than people with cancers that are more challenging to treat, such as stomach and pancreatic cancers, and that more research is needed to interpret these findings.

The approach is already routine for some cancer patients, such as women and men with breast cancer tumors that have high levels of a protein called HER2, or lung cancer tumors with mutations in the EGFR gene.

«We know that patients with BRCA mutations are at high risk for developing breast, as well as pancreatic, ovarian, prostate and other cancers, and we have learned over time that BRCA plays a very important role in DNA damage repair.

Because bazedoxifene has already undergone safety and efficacy studies as a treatment for osteoporosis, it may be a viable near - term option for patients with advanced breast cancer whose tumors have become resistant to other treatment options, Wardell reported.

Kontos adds that a greater role for aspirin would be welcomed by many at - risk patients, as current drugs aimed at reducing risk, such as tamoxifen and raloxifene, have significant side effects and do not prevent ER - negative breast cancer.

The trial investigated the drug in two separate cohorts of patients: Cohort A, which included 170 patients with heavily pretreated metastatic triple negative breast cancer (mTNBC) regardless of PD - L1 expression, and Cohort B, which included 52 patients with PD - L1 - positive tumors who received it as first - line therapy.

Just as no two people possess the same genetic makeup, a recent study has shown that no two single tumor cells in breast cancer patients have an identical genome.

«Double mastectomy tied to more missed work: As more breast cancer patients are choosing to remove both breasts, researchers examine the impact this aggressive surgery has on their employment.»

However, even with treatment up to one in five patients will see their DCIS come back, either as DCIS or as invasive breast cancer.

Clinicians are currently worried that breast cancer patients with low or absent BRCA1 may become resistant to therapeutic agents such as Olaparib.

Should the results be confirmed by further studies, it is possible that patients with certain genetic changes in BRCA1 could be identified as being at higher risk of breast and ovarian cancer.

By examining patient tissue samples and information about whether each person had had a recurrence, the scientists discovered that high FAK activity was linked to the disease returning, either as DCIS or invasive breast cancer.

By performing a genome - wide screen in breast cancer cells, Dr. Oesterreich and her colleagues identified a gene called HOXC10 as one that the cancer seems to modify to allow continued tumor growth in patients whose cancer becomes resistant to traditional therapies.

It will monitor 11,000 patients for as long as 12 years to investigate whether taking aspirin daily stops the recurrence of some cancers, including stomach and breast cancer.

This shows promise for breast cancer patients as diagnosing and treating the breast cancer at early stages means there is a greater chance of preventing cancer cells spreading to other tissues, such as the lungs, brain and bone.

About 20 percent of breast cancer patients have overexpressed growth receptors, known as Her2 + receptors, on the cancer cells, which cause uncontrolled tumor growth.

«We hope that physicians will consider treating hypertension that may arise in breast cancer patients,» Dr Lenneman says, suggesting that existing treatments such as beta - blockers may mitigate the damage.

Hormonal therapy for patients with estrogen - or progesterone - positive breast cancers can reduce the risk of cancer recurrence by as much as 50 percent.

Dr. Parda, who practices oncology in Pittsburgh, says that many types of physicians are likely to be a part of a patient's cancer care team including a medical oncologist, breast surgeon, surgical oncologist, plastic surgeon, and radiation oncologist as well as their ob / gyn.

The commercial testing occurred because the patients had a severe family history of breast cancer, defined as a family with three or more relatives affected by breast or ovarian cancer.

Previous in vitro studies conducted by researchers in other countries showed that this molecule was able to reduce the multiplication and increase the mortality of cells from melanoma, the most aggressive type of skin cancer, as well as breast cancer and neuroblastoma, a tumor that typically affects patients aged 15 or younger.

All nine patients also had lost portions of chromosomes containing one or both BRCA1 and BRCA2 genes, which have long been linked to hereditary as well as sporadic breast and ovarian cancers.

After chemotherapy, as many as 65 per cent of patients with breast cancer report memory lapses, difficulty concentrating, taking longer to complete tasks and difficulty multitasking.

They also showed that drugs against a type of breast tumor called HER2 positive breast cancer — such as the dual ERBB2 / EGFR inhibitor lapatinib — potentially could benefit more patients than currently receive them, if analysis of the tumor proteins is taken into consideration.

While improved diagnostic and treatment methods have reduced the overall death rate from breast cancer, the study authors note, that reduction has not been as pronounced among African American patients.

The drugs are already approved for treatment of patients with advanced breast cancer as well as ovarian, pancreatic and certain lung cancers.

Patients with a history of breast cancer or lymphoma were more than three times as likely to develop heart failure — a condition in which the heart can't pump enough blood to meet the body's needs — compared with a similar group of patients who did not have cancer, according to data being presented at the American College of Cardiology's 67th Annual Scientific Patients with a history of breast cancer or lymphoma were more than three times as likely to develop heart failure — a condition in which the heart can't pump enough blood to meet the body's needs — compared with a similar group of patients who did not have cancer, according to data being presented at the American College of Cardiology's 67th Annual Scientific patients who did not have cancer, according to data being presented at the American College of Cardiology's 67th Annual Scientific Session.

As a next step, Guha, Avadhani and colleagues plan to extend this study to in vivo mouse models and will also investigate these mechanisms in tumor samples from human breast cancer patients.

The result: Cancer patients» breast tissue contains four times as much of a key quinone precursor as that of healthy women, as well as indicators of a high demand for quinone janitorial services — a sure sign of overabundant estrogen quinones, Rogan says.

People with breast cancer or lymphoma were three times as likely to develop heart failure within five years of their cancer diagnosis, and 20 years following cancer treatment were still nearly twice as likely to have been diagnosed with heart failure compared to similar patients who didn't undergo cancer therapy.

In preliminary findings presented at the 2016 San Antonio Breast Cancer Symposium, researchers showed that older patients were as likely as younger patients to receive targeted therapy and enroll in therapeutic trials based on their sequencing results.

UNC Lineberger researchers reported at the San Antonio Breast Cancer Symposium they have identified biomarkers they believe can be used as part of a larger model to predict how patients with HER2 - positive operative breast cancer will respond to the targeted treatment trastuzumab, commercially known as Herceptin, and chemothBreast Cancer Symposium they have identified biomarkers they believe can be used as part of a larger model to predict how patients with HER2 - positive operative breast cancer will respond to the targeted treatment trastuzumab, commercially known as Herceptin, and chemothCancer Symposium they have identified biomarkers they believe can be used as part of a larger model to predict how patients with HER2 - positive operative breast cancer will respond to the targeted treatment trastuzumab, commercially known as Herceptin, and chemothbreast cancer will respond to the targeted treatment trastuzumab, commercially known as Herceptin, and chemothcancer will respond to the targeted treatment trastuzumab, commercially known as Herceptin, and chemotherapy.

In early clinical trials of these drugs, we noticed that in some breast cancer patients the tumors didn't just remain the same size — as would be expected with drugs that interfere with cell division — but began to recede, sometimes quite dramatically, said Goel.»

Cecelia Bellcross, director of Emoryâ $ ™ s genetics counseling program and an expert on breast cancer genetics counseling, reports that â $ œin general, the clinical genetics community is jumping up and down, as are a lot of genetics lab directors and definitely patient advocacy groups.â $